NEW YORK (GenomeWeb) – A genomic study of non-invasive bladder cancer has identified genomic subtypes of the disease, along with pathways that are more frequently altered relative to muscle-invasive forms of the disease.
“Our improved ability to identify these specific molecular features of individual tumors should allow a more personalized approach to therapy and disease management in the future,” senior author Margaret Knowles, a molecular oncology researcher at Leeds Institute of Cancer and Pathology, said in a statement.
Knowles and colleagues from the UK and US used low-coverage genome sequencing-based copy number analyses, array comparative genomic hybridization, exome sequencing, and/or expression profiling to characterize tumor and matched normal samples from 140 individuals with non-invasive bladder cancer. From these data, they defined chromosomally stable and unstable genomic subtypes of non-invasive bladder cancer, which appeared to differ in their recurrence-free survival patterns.
As reported in Cancer Cell online today, the team identified recurrent changes affecting genes involved in chromatin modification, which appeared more common in the non-invasive bladder cancers than in muscle-invasive bladder cancers. The analysis also uncovered mutations in the histone demethylase enzyme-coding gene KDM6A that marked more female than male cases.
Roughly three-quarters of the bladder cancer cases diagnosed globally